Standard Lithium Ltd vs Smith & Nephew plc — how do they compare? Standard Lithium Ltd trades at $1.58 (market cap $398.07M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 27.9× Standard Lithium Ltd's market cap, and Smith & Nephew plc pays a 2.95% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and Smith & Nephew plc for 121 Days on average.
| SLI | SNN | |
|---|---|---|
Market Cap | $398.07M | $11.10B |
Volume | 1,564,155 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $37.17 |
52-Week Low | $1.58 | $26.42 |
Typical Hold Time | 23 Days | 121 Days |
Enterprise Value | $260.98M | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with mixed signals from technical indicators showing bearish moving averages but oversold RSI readings. The company remains pre-revenue with negative profitability metrics (ROE -15.55%, ROA -14.17%) but has shown improving quarterly EPS performance, beating expectations in recent quarters. Recent developments include progress toward a final investment decision for the South West Arkansas lithium project and new customer offtake agreements.
The investment case hinges on successful project execution, with analyst consensus strongly bullish (100% buy ratings) and a $3.83 price target representing 138% upside. Key risks include the pre-revenue status, negative cash flow from operations, and project timeline execution. The stock offers high-risk, high-reward exposure to lithium development with significant government and institutional support.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →